Iterum Therapeutics (NASDAQ:ITRM) Shares Up 2.1% – Should You Buy?

Shares of Iterum Therapeutics PLC (NASDAQ:ITRM) rose 2.1% during trading on Tuesday . The company traded as high as $0.3599 and last traded at $0.3425. Approximately 418,814 shares traded hands during mid-day trading, a decline of 51% from the average daily volume of 853,949 shares. The stock had previously closed at $0.3355.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Iterum Therapeutics in a report on Monday, December 22nd. Wall Street Zen cut shares of Iterum Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $9.00.

Iterum Therapeutics Stock Performance

The business has a fifty day simple moving average of $0.38 and a 200-day simple moving average of $0.59. The firm has a market cap of $18.25 million, a price-to-earnings ratio of -0.46 and a beta of 2.87.

Iterum Therapeutics (NASDAQ:ITRM) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.07). The company had revenue of $0.39 million for the quarter. On average, equities analysts anticipate that Iterum Therapeutics PLC will post -0.86 earnings per share for the current year.

Institutional Investors Weigh In On Iterum Therapeutics

A number of hedge funds have recently added to or reduced their stakes in ITRM. Virtu Financial LLC bought a new position in shares of Iterum Therapeutics during the 3rd quarter worth approximately $32,000. Jane Street Group LLC acquired a new position in shares of Iterum Therapeutics during the 2nd quarter valued at $92,000. OneDigital Investment Advisors LLC boosted its stake in Iterum Therapeutics by 18.6% during the third quarter. OneDigital Investment Advisors LLC now owns 191,000 shares of the company’s stock worth $128,000 after acquiring an additional 30,000 shares in the last quarter. Finally, Apollon Financial LLC grew its holdings in Iterum Therapeutics by 151.8% in the fourth quarter. Apollon Financial LLC now owns 630,250 shares of the company’s stock worth $211,000 after purchasing an additional 380,000 shares during the period. 9.21% of the stock is currently owned by institutional investors.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc is a clinical-stage biopharmaceutical company focused on the development and commercialization of anti-infective products targeting drug-resistant bacterial infections. The company’s research efforts are centered on novel therapeutic agents designed to address serious community-acquired and hospital-acquired infections where current treatment options are limited by emerging resistance.

The company’s lead product candidate, sulopenem, is being evaluated in both intravenous and oral formulations for the treatment of complicated urinary tract infections (cUTI) and intra-abdominal infections (IAI).